The company said its Q4 2023 revenue was $902 million, up 9% on a reported basis and 8% on an organic basis from the prior year period. Full-year revenue was $3,661 million, up 9% on both a reported and organic basis.

1. 01

   The company said its Q4 2023 revenue was $902 million, up 9% on a reported basis and 8% on an organic basis from the prior year period. Full-year revenue was $3,661 million, up 9% on both a reported and organic basis.

2. 02

   IDEXX said fourth quarter diluted EPS was $2.32, up 13% as reported and 17% on a comparable basis for Q4. Full-year EPS was $10.06, up 25% as reported and 29% on a comparable basis. Full-year EPS included the effects of the discrete in-license of technology for $80 million and the customer contract resolution for $16 million.

3. 03

   The company said CAG Diagnostics recurring revenue rose 11% as reported and 10% organically in Q4. IDEXX VetLab consumables grew 14% as reported and 13% organically, and the operating margin for Q4 was 27.2%.

4. 04

   The company gave revenue guidance for 2024 of $3,930 million to $4,040 million, reflecting reported growth of 7.5% to 10.5%, and EPS guidance of $10.84 to $11.33. The company said its EPS guidance includes a negative EPS growth impact of about 2% from the 2023 customer contract resolution.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.